AIM: Aim of the study was to retrospectively analyze the clinical parameters that contribute to the therapeutic outcome of @entity6757 analogues. METHODS: We enrolled 106 @entity1 with @entity6 ( @entity6 ), treated with liraglutide (N.=69) or exenatide (N.=37) for longer than three months. The @entity1 were divided into two groups: good responders and poor responders to @entity6757 analogues, based on pretreatment and post-treatment HbA1c levels. Good responders were those whose HbA1c level had decreased by 1% or more, or maintained at less than 7%. All other @entity1 were categorized as poor responders. We used univariate and multivariate analyses to assess pretreatment parameters between the two groups. RESULTS: Approximately 35% of the @entity1 were poor responders. Our analysis of the pretreatment clinical parameters revealed that number of anti- @entity6 agents and use of @entity4136 were significantly associated with poor response to liraglutide (P=0.02 and P=0.03, respectively) in a multivariate analysis. We were not able to find any candidate related to clinical response to exenatide. CONCLUSION: Our study showed that the therapeutic effects of @entity6757 analogues on @entity6 @entity1 were heterogeneous. @entity6 @entity1 who require multiple anti- @entity6 agents, especially @entity4136 , do not benefit from liraglutide treatment.

Multiple drug combination of anti- XXXX agents as a predictor for poor clinical response to liraglutide.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity4136 :: ('CHEBI:26831', 'Chemical') :: ['sulfonylurea'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetic', 'T2DM', 'type 2 diabetes mellitus'] @entity6757 :: ('100125288', 'Gene') :: ['GLP-1']
@entity6 :: (MESH:D003920,Disease) :: ['diabetic']
